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AbstrACt
Introduction Obesity and associated diseases place 
a severe burden on healthcare systems. Behavioural 
interventions for weight loss (WL) are successful in the 
short term but often result in weight regain over time. 
Self-regulation of eating and activity behaviours may 
significantly enhance weight loss maintenance (WLM) and 
may be effectively augmented by contextual behavioural 
approaches to emotion regulation. The NoHoW trial tests 
the efficacy of a theoretically informed, evidence-based 
digital toolkit using a mobile-enabled website, activity 
trackers and Wi-Fi scales for WLM aiming to target (1) 
self-regulation and motivation, and (2) emotion regulation 
in adults who achieved clinically significant (≥5%) WL in 
the previous 12 months (initial body mass index (BMI) 
≥25 kg/m2).
Methods and analysis The study is an 18-month, 
3-centre, 2×2 factorial single-blind, randomised controlled 
trial, which recruited 1627 participants achieving ≥5% 
WL between March 2017 and March 2018. Participants 
are randomly allocated to one of four arms: (1) self-
monitoring only (self-weighing and activity tracker), (2) 
self-regulation and motivation, (3) emotion regulation 
or (4) combined self-regulation, motivation and emotion 
regulation. Participants attend four clinical investigation 
days at 0, 6, 12 and 18 months and are instructed to use 
the digital toolkit for 18 weeks during the first 6 months 
and at their discretion for the remaining 12 months. The 
primary outcome is change in weight (kg) at 12 months 
from baseline. Secondary outcomes are body composition 
(eg, bioimpedance analysis), health biomarkers (glycated 
haemoglobin, lipids, blood pressure, hair cortisol), 
dietary intake, physical activity, sleep, motivational, self-
regulatory, emotion regulatory moderators/mediators of 
WLM, engagement, user experience, acceptability and 
cost-effectiveness of the interventions.
Ethics and dissemination Ethical approval was granted 
by Institutional Ethics Committees at the Universities of 
Leeds (17–0082; 27 February 2017), Lisbon (17/2016; 
20 February 2017) and Capital Region of Denmark (H-
16030495, 8 March 2017). Results will be published in 
scientific journals.
trial registration number ISRCTN88405328.
strengths and limitations of this study
 ► The first project to develop and evaluate (via ran-
domised controlled trial) an information and commu-
nications technology toolkit combining continuous 
tracking of physical activity and body weight with 
theoretically informed, evidence-based digital inter-
ventions targeting self-regulation and motivation, 
and emotion regulation in a 2×2 design, to target 
long-term weight management.
 ► The 2×2 factorial design is a step forward from a 
conventional two-armed trial to determine the effect 
of self-regulation/motivation, emotion regulation inter-
ventions and their interactions on weight and health 
outcomes.
 ► Analyses of primary outcomes will test the hy-
potheses that self-regulation of energy balance 
behaviours improves longer term weight outcomes 
and that emotion regulation strategies help prevent 
weight relapse. Moderator analysis will determine if 
participant psychological/behavioural profiles pre-
dict response to self-regulation or emotion regula-
tion interventions. Mediation analyses will examine 
mechanisms of action by which self-regulation and 
emotion regulation-based approaches affect energy 
balance behaviours, weight and health.
 ► Participants are blinded to study allocation, but they 
can access similar interventions from other real-world 
sources.
 ► There was no zero-intervetion control. The active 
control arm includes self-monitoring of physical 
activity and weight but the inclusion of the Fitbit 
devices across all arms potentially contaminates or 
diminishes the effect of self-regulatory components. 
Social support was excluded as a potential contam-
inant of the digital intervention.
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IntroduCtIon
Overweight, obesity and associated diseases are key soci-
etal challenges. Obesity prevalence accounts for 3%–8% 
of health costs and 10%–13% of deaths in Europe.1 This 
translates into €59 billion a year in direct, and an esti-
mated €118–€236 billion in indirect, healthcare costs.2 
These costs are set to rise in parallel with obesity prev-
alence.3 Approximately 40% of the adult population in 
Europe report engaging in at least one weight control 
attempt in the previous 12 months.4 Existing communi-
ty-based programme support initial weight loss (WL) but 
are subject to high attrition or weight regain, limiting 
longer term effectiveness.5 6 The obesogenic environment 
and asymmetry of human energy balance (EB) regula-
tion facilitates weight gain, while society criticises people 
suffering from overweight and obesity, leading to stress 
and negative emotions, which can undermine weight loss 
maintenance (WLM) attempts.7 8 Effective support for 
WLM or the prevention of weight regain needs to address 
sustained changes in EB behaviours (dietary, physical 
activity and weight control) and additional emotional/
psychosocial challenges that may undermine planned 
healthy behaviours.
self-regulation and motivation
Core features of effective WLM interventions include 
behaviour change techniques in line with self-regula-
tion theories such as (1) self-monitoring of weight and 
behaviour; (2) goal-setting: agreement of clear weight 
targets/trigger points for weight control efforts; (3) feed-
back on behaviour and weight; (4) action plans for weight 
control through dietary and physical activity behaviours; 
and (5) plans to cope with risk factors for weight regain 
and relapse prevention (eg, problem solving).9–15 Further, 
self-determined autonomous motivation has been consis-
tently associated with change in EB behaviours for obesity 
management.16 17 Interventions rooted in Self-Determina-
tion Theory may offer a promising approach to sustained 
EB and weight control.12 17 A recent systematic review 
exploring psychological mediators of sustained effects in 
diet and lifestyle obesity interventions found that higher 
levels of autonomous motivation, self-efficacy, self-regula-
tion skills, flexible eating restraint and positive body image 
were mediators of medium-term to long-term weight 
control.18 The combination of motivational and volitional 
processes of EB behaviours can contribute to effective 
WLM; that is, it appears those who are adequately moti-
vated and who implement intentions tend to both initiate 
and maintain such changes.19–21 However, physical activity 
and dietary interventions based on current behaviour 
change theories characteristically achieve significant, but 
small and heterogeneous effects.22 Additional psycholog-
ical processes, such as emotion regulation, can potentially 
have incremental beneficial effects on the behavioural 
changes that promote WLM.23
Emotion regulation
Individuals with obesity or those trying to lose weight 
can experience increased stress, depression, anxiety and 
weight-related stigma24 25 which may undermine weight 
control attempts. Repeated attempts at WL followed by 
weight regain can have a negative emotional impact, 
leading to self-critical thoughts and negative emotions. 
For some, ‘comfort eating’ may be a means of coping 
with these negative experiences, potentially derailing 
strategies of planned behaviour.26–28 Relapse preven-
tion models include contextual behavioural (CB)-based 
emotion regulation strategies such as compassion, accep-
tance and mindfulness.29–31 Evidence suggests that mind-
fulness and acceptance of undesired internal experiences 
(eg, negative emotions or self-criticism) and compassion 
for the self and others may help some individuals adopt 
adaptive behaviours that are congruent with their weight 
goals or values.32–36 Mindfulness-based interventions show 
promise in changing obesity-related eating behaviours 
(eg, binge eating and emotional eating), lowering depres-
sion levels and improving WLM.37 Augmenting current 
self-regulatory approaches with CB emotion regulatory 
approaches could lead to more effective WLM.32–36
digital behaviour change interventions
Recently, there has been interest in digital interventions 
to promote and maintain health.38 Digital solutions, such 
as smartphone applications and wearables, can be effec-
tive in supporting WLM if they are evidence-based, apply 
a choice of behaviour change techniques with individual-
ised feedback,22 39 40encourage the use of self-regulatory 
techniques (eg, self-monitoring) and develop intrinsic 
motivation.41 Digital solutions are potentially cost-ef-
fective and scalable to large populations, which could 
engage citizens in healthcare innovations that are conve-
nient and effective for weight management in the face of 
limited public budgets.42 To date, most commonly avail-
able weight management applications miss key evidence-
based approaches for longer term behaviour change.43 44
study objectives and hypotheses
The effectiveness of long-term evidence-based digital inter-
ventions and strategies to support WLM is limited.45 The 
study’s primary objectives are to evaluate whether using 
a new digital toolkit is effective for WLM by improving 
(1) self-regulation and motivation, (2) emotion regula-
tion or (3) these factors in combination, compared with 
(4) control (generic toolkit content, regular self-weighing 
and Fitbit use), in 1627 participants at three European 
centres. We hypothesise that the combined interven-
tion will be more effective for WLM compared with the 
self-regulatory or emotion regulatory interventions alone, 
which will also be more effective than the control group.
Secondary objectives are to determine (1) how the 
intervention affects health markers (eg, levels of glycated 
haemoglobin (HbA1c)) and body composition; (2) 
examine the intervention impacts on physical activity, 
sleep, dietary intake, depression, anxiety, stress, quality of 
life and well-being; (3) examine mediators of WLM, such 
as self-regulation (eg, planning capacity), motivation 
(eg, autonomous motivation) and emotion regulation 
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Figure 1 Trial design. RCT, randomised controlled trial.
processes (eg, self-compassion); (4) analyse baseline 
moderators (eg, gender, body mass index (BMI)) to iden-
tify participants who are more responsive to motivational 
and behavioural self-regulatory or CB-emotion regula-
tory approaches for WLM; (5) conduct quantitative and 
qualitative assessment of user-experience, acceptability, 
engagement and dropout; (6) examine intervention 
cost-effectiveness; and (7) to determine the efficacy of 
individualised feedback from data on physical activity 
self-tracking.
MEthods
trial design and setting
The NoHoW trial is a three-centre (University of Leeds 
(UK), The Parker Institute (Denmark) and University 
of Lisbon (Portugal)) 2×2 factorial, randomised, single-
blind, controlled trial testing the proof-of-concept of a 
digital toolkit for WLM. The study duration is 18 months 
with a follow-up at 6, 12 and 18 months postbaseline 
(figure 1). The study is conducted between March 2017 
and September 2019 in academic research institutes. In 
total, 1627 participants (~542 per centre) were enrolled 
and randomised into one of four intervention arms: 
(1) active control arm (consisting of generic toolkit 
content, self-weighing and activity trackers, only); (2) 
self-regulation and motivation arm; (3) emotion regula-
tion arm; and (4) combined motivation/self-regulation 
and emotion regulation arm (figure 1). The protocol is 
harmonised across trial centres using Good Clinical Prac-
tice guidance, research-grade translation/backtranslation 
of trial materials, two training workshops and weekly trial 
management meetings. The trial registration data set is 
displayed in table 1. The final protocol (V2.1 20/09/2017) 
was approved by the Trial Steering Committee (TSC) and 
adheres to the Standard Protocol Items: Recommenda-
tions for Interventional Trials guidelines.46
Participants
Table 1 describes the inclusion/exclusion criteria for the 
trial. Prior to randomisation, potential participants are 
asked to provide documented verification (by a health 
professional, WL counsellor/friend, WL programme 
record booklet, diary or smartphone app or before/after 
photographs47) that they have achieved a clinically signif-
icant WL of >5% during the previous 12 months.
study recruitment
The study recruitment and intervention schedule is 
outlined in table 2. Centre-specific recruitment strate-
gies were adopted for 12 months (March 2017–March 
2018) and included commercial WL programme (UK, 
Slimming World); the Copenhagen Municipality weight 
management services, Dieticians from the Danish 
Association for Dieticians and commercial slimming 
companies (eg, Sense, Henrik Duer and Per Nielsen); 
registered clinical dieticians/nutritionists who provide 
weight management services in Lisbon; leisure centres; 
and local/national media coverage and advertisements. 
All participants were directed to country-specific recruit-
ment websites (http:// uk. nohow. eu; http:// dk. nohow. 
eu; http:// nohow. fmh. ulisboa. pt) and completed an 
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Table 1 WHO trial registration data set
Data category Information
Primary registry and trial identifying 
number
ISRCTN: 88 405 328
Date of registration in primary registry 16/12/2016
Secondary identifying numbers H2020-EU.3.1 Grant agreement ID: 643 309
Source(s) of monetary or material 
support
European Commission, Horizon 2020—EU Framework Programme for Research and Innovation
Primary sponsor University of Leeds, Leeds, UK
Secondary sponsor(s) The Parker Institute, Copenhagen, Denmark
University of Lisbon, Lisbon, Portugal
Contact for public queries Prof. James Stubbs (r.j.stubbs@leeds.ac.uk)
School of Psychology
Faculty of Medicine and Health
University of Leeds
Leeds
LS2 9JT
UK
+44 (0)113 343 3476
Contact for scientific queries Professor James Stubbs (r.j.stubbs@leeds.ac.uk)
Public title NoHoW: Evidence-based ICT tools for weight loss maintenance
Scientific title A 2×2 randomised controlled trial to evaluate the effectiveness of evidence-based ICT behaviour 
change tools for weight loss maintenance in overweight/obese adults after clinically significant 
weight loss.
Countries of recruitment 1. University of Leeds (UK).
2. The Parker Institute (Denmark).
3. University of Lisbon (Portugal).
Health condition(s) or problem(s) studied Adults aged 18 or older who have intentionally lost at least 5% of their body weight in the last 12 
months, and initially had a BMI of 25 or more.
Intervention(s) Participants are assigned to one of four interventions:
1. Self-monitoring only (self-weighing and activity tracker).
2. Self-regulation and motivation.
3. Contextual behavioural science-based emotion regulation (CBS-emotion regulation).
4. Combined self-regulation, motivation and CBS-emotion regulation.
Key inclusion and exclusion criteria Inclusion criteria:
1. Aged 18 years or older.
2. BMI (prior to weight loss) of ≥25 kg/m2.
3. Verification of ≥5% of weight loss in the last 12 months and remain 5% below their highest 
weight.
4. Ability to use a smartphone and have access to smart phone, tablet or computer with internet 
access and Wi-Fi.
5. Ability to use standing scales for weight measurements and must not be over 150 kg (the scale 
limit 158 kg)
Exclusion criteria:
1. Inability to give informed consent.
2. Lost weight due to illness or surgical procedures, including bariatric procedures.
3. Pregnant or breastfeeding.
4. Involvement in another research intervention study that confound with the aims of NoHoW 
(excluding local health interventions and weight management services).
5. Inability to follow written material or telephone conversations in the English, Danish or 
Portuguese language (depending on the centre).
6. Diagnosed with an eating disorder (eg, anorexia nervosa, bulimia nervosa or purging disorder).
7. Diagnosed with any condition that may interfere with increasing mild to moderate physical 
activities and which is unstable (ie, untreated or unable to be controlled by medication).
8. Recent diagnosis with type 1 diabetes.
9. Extensive planned travel, that is, moving away or long-term travel abroad (eg, more than 
4 weeks).
10. Living in the same household as existing participant in the trial.
Study type Interventional, 2×2 factorial randomised controlled trial.
Date of first enrolment 20 March 2017
Target sample size 1600
Recruitment status Completed (31/03/2018), no longer recruiting.
Continued
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Data category Information
Primary outcome(s) Weight (kg)
Key secondary outcomes 1. Body composition: (eg, fat mass and fat-free mass) and waist/hip ratio.
2. Biomarkers: blood pressure, heart rate, cortisol (hair samples), HbA1c, cholesterol.
3. Behavioural: physical activity, sleep and dietary intake.
4. Psychological moderators and mediators of change for: self-regulation and motivation (eg, action 
planning and coping, self-efficacy); CBS-emotion regulation (eg, weight focused self-criticism, 
five dimensions of mindfulness); stress management (eg, perceived stress scale, depression, 
anxiety and stress); and quality of life and well-being.
5. Process evaluation
6. Cost-effectiveness analysis
BMI, body mass index; ICT, information and communications technology.
Table 1 Continued
Table 2 Study recruitment and intervention schedule (Standard Protocol Items: Recommendations for Interventional Trials 
2013 guidelines)
TIME POINT
Study duration
Recruitment Baseline 6 months 12 months 18 months
t0 t1 t2 t3 t4
RECRUITMENT
  Screening X
  Informed consent X
  Randomisation and allocation X
INTERVENTION
  Fitbit device training X
  Intake24 (food diary) training X
  Toolkit training (after 
randomisation)
X
  Arms 2–4 active intervention ♦———————♦
  Arms 2–4 follow-up ♦——————————————————♦
  Arm 1 (control) intervention ♦——————————————————————————♦
online eligibility screener using Qualtrics. The eligibility 
screener categorised respondents as eligible, potentially 
eligible (wait-list) and ineligible. Eligible individuals were 
contacted for a telephone screening interview, provided 
with study information, medical history questions and 
the Physical Activity Readiness Questionnaire.48 Eligible 
participants were invited to a clinical investigation day 
(CID) where informed consent was obtained by research 
staff before randomisation (online supplementary file 1). 
Participants are reconsented before each subsequent visit 
and excluded if they become ineligible.
Public involvement
Members of the public that matched the study’s inclu-
sion criteria at the three trial centres were consulted via a 
survey to inform the recruitment strategies, trial conduct, 
questionnaires, assessment of burden and reviewing 
or testing the intervention content at all trial centres. 
During the toolkit development stage, the public were 
involved in two ways. First, a panel of 10 people, matching 
the trial criteria, tested the toolkit V.1 written in English 
for 1 month in the UK. A mixed methods approach was 
used for the analysis of the data assessing technical matu-
rity of the intervention and user experiences, through 
questionnaires (quantitative data), interviews (qual-
itative data), TK usage log data and data from wireless 
scales and activity trackers (Fitbit). These analyses will 
be published in a separate paper. The results were used 
to inform toolkit V.2. Toolkit V.2 was then tested for 18 
months using a panel of 30 people (10 in each centre) 
starting 3 months before the launch of the trial. Trial staff 
regularly collaborated with the panel to identify techno-
logical glitches that could be corrected early on so as not 
to impact on the main trial participants.
randomisation and blinding
Participants were randomly allocated to treatment arms 
by researchers using an online trial administration 
portal. Adaptive stratified sampling using minimisation49 
was embedded in the portal using the R-programme (R 
Foundation for Statistical Computing, Vienna, Austria) 
by the study statistician GH. This minimises differences 
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Figure 2 Toolkit example (arm 4).
in age, WL in the previous 12 months and current BMI 
between treatment arms and stratified by gender and 
centre. Participants were blinded to study allocation. The 
research team were not blinded due to the need to train 
participants in arm-specific toolkit versions. The statisti-
cian (GH) is independent from data collection but not 
blinded during analyses due to inclusion of the arm allo-
cation number. Independent researchers analysing hair 
cortisol are blinded to group allocation. No preliminary 
or ancillary analysis of outcome data between interven-
tion arms were conducted prior to data-lock (12 months).
Interventions
The toolkit is a mobile-enabled website, delivered as a port-
folio of embedded tracking technologies, mini-apps and 
web resources (figure 2) accessible via computer, tablet 
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and mobile phone. The tracking technologies consist of 
an activity and sleep tracker (Fitbit Charge 2) and smart 
wireless body weight scale (Fitbit Aria). Participants were 
asked to wear the Fitbit Charge 2 at all times and to weigh 
themselves ≥twice weekly. All arms include instructions 
for self-weighing and use of activity trackers. Arms 2 and 
4 include individualised weekly feedback about weight 
trajectories. Guidance for complex interventions was 
followed during the toolkit development specifying the 
intervention logic models and theory-driven behaviour 
change techniques,50 which will be detailed in a separate 
publication.
Arm 1 (active control, self-monitoring, only)
The active control arm includes a toolkit dashboard 
containing weight, steps and sleep graphs using data 
from the Fitbit devices, healthy eating and mood data 
(self-scored on a five-point scale), a diary to populate with 
notes from these five tiles and a help tile. The content is 
generic and does not relate to any theoretically informed, 
evidence-based behaviour change approaches.
Arms 2–4
After randomisation, participants received standardised 
training from researchers during the first CID, specific 
to their arm allocation. Trial arms 2–4 include the same 
components as arm 1 but participants also receive a 
personal virtual road map (the ‘NoHoW Journey’) with 
intermediate destinations represented in that map by 
circles, each comprised of evidence-based theoretically 
informed thematic modules targeting self-regulation 
and motivation (arm 2), emotion regulation (arm 3) 
and combined self-regulation and emotion regulation 
(arm 4). Arm 4 includes the same number of thematic 
modules as arms 2 and 3. Each weekly module opens 
into submodules. The active intervention involves 18 
weekly sessions delivered throughout a 6-month period. 
Users are encouraged to complete ≥1 submodule per 
week following the sequence in the road map, consisting 
of videos/audios, interactive graphs, text, images, ques-
tionnaires and mini-apps. Weekly arm-specific emails are 
sent during the active 6-month intervention phase, which 
provide WLM information, suggestions and reminders to 
visit specific content. The toolkit automatically sends an 
email notifying participants to slow down if they complete 
three sessions ahead of schedule. After 6 months, they are 
encouraged to revisit the toolkit for a further 12 months 
at their discretion.
Individualised feedback is a component of the self-reg-
ulation and motivation arms (arms 2 and 4) automatically 
provided by the toolkit in response to the individual’s 
weight trajectory. Feedback is generated from the data 
extracted from three sources: (1) weight from the Fitbit 
Aria scales; (2) activity and sleep from the Fitbit Charge 
2; and (3) user engagement with the toolkit, including 
day of the week. After daily usage patterns are analysed, 
feedback is displayed in the toolkit consisting of one of 
a set of short statements (eg, “your weight management 
appears better when you are more active”).
Adherence
The toolkit sends automated weekly emails to participants 
to encourage engagement, prompt log-in and recom-
mends sessions to complete (arms 2–4 only). The control 
group receives the same number of emails but with links 
to generic content (eg, topical diet/health information). 
Intervention adherence is continuously monitored by 
collecting information on the number of days since users 
last logged into the toolkit and the number of days since 
the last synchronisation between the Fitbit devices and 
data-hub. If no activity is detected after 21, 28 and 35 
days, three attempts are made to contact participants by 
email. After 42 days of no activity, researchers telephone 
participants to resolve issues. Reasons for no activity are 
recorded.
Assessments
The primary outcome is change in weight (kg) between 
baseline and 12 months (primary endpoint). Follow-up 
measures for WLM are completed at month 18 for 
comparability with other longitudinal studies.22 All phys-
ical measurements are taken after a 10–12 hour overnight 
fast by trained research staff. Measures are taken at all 
four time points (baseline, 6, 12 and 18 months) except 
HbA1c, lipids and hair cortisol (baseline and 12 months 
only) and process evaluation measures (1, 3, 6 and 12 
months only). The study schedule and information for all 
measures is in online supplementary file 2.
Participant retention
Randomised participants are contacted at least 2 weeks 
before each visit and sent an email/text reminder. If 
participants deviate from planned assessments, three 
attempts are made to contact them by phone, email 
and a final written letter across 1 month. At least weight 
(primary outcome) is obtained if possible.
Primary outcome
Change in weight (kg) at 12 months from baseline
Body weight (±0.1 kg) is measured using a Seca 704 s 
instrument (SECA, Germany) in participants wearing 
light clothing. Participants are asked to weigh themselves 
at least twice weekly, in the morning after voiding and 
before eating using the Fitbit Aria scales for 18 months.
secondary outcome measures
Body composition and height
Multifrequency whole bioimpedance spectroscopy 
is measured by ImpediMed (SFB7, Queensland, 
Australia), which measures impedance over a spectrum 
of frequencies for the estimation of body composition. 
Hanai mixture theory equations and standard resistivity 
constants51 are used to calculate fluid volumes to esti-
mate total body water. Height (±0.1 cm) is measured 
with participants barefoot, using a Seca 704 s instrument 
(SECA, Germany). See online supplementary file 2.
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Waist–hip ratio
Waist and hip measurements are taken according to the 
WHO’s guidance. A tape measure is used to record the 
hip and waist circumference to the nearest centimetre.52 
The waist–hip ratio is calculated by dividing hip and waist 
circumference.
biomarkers
HbA1c and cholesterol
Fasted capillary blood samples are collected to determine 
HbA1c (mmol/mol, %), estimated average glucose (eAG, 
mol/L) and full lipid profiles, including total cholesterol, 
low-density lipoprotein, high-density lipoprotein (HDL), 
triglycerides, non-HDL and cholesterol/HDL (mmol/L) 
assayed using a benchtop analyser (Alere Afinion AS100 
Analyser, Alere, Stockport, UK).53
Blood pressure heart rate
Systolic and diastolic blood pressure (BP) and resting 
heart rate (HR) (Microlife BP A2 Basic, Gentle Tech-
nology, Microlife, Clearwater, FL, USA,) are measured 
three times with the participant at rest in the sitting posi-
tion. The mean value is recorded.
Hair cortisol
Hair samples are collected by cutting a small tuft of hair 
close to the scalp to measure the stress hormone, cortisol, 
and analysed following a previously described protocol54 
(online supplementary file 2).
Physical activity
Physical activity is measured by the self-reported Inter-
national Physical Activity Questionnaire (IPAQ)55 and 
Activity Choice Index (ACI).56 Minute-by-minute physical 
activity data and heart rate are measured by the Fitbit 
Charge 2 for the study duration.
Sleep quality and quantity
The Fitbit Charge 2 estimates sleep quantity (hours/
minutes) and quality (stages of sleep). Data are collected 
throughout the trial.
Dietary intake and eating behaviour
Four consecutive 24-hour-web-based dietary recalls, 
including at least 1 weekend day, are collected within 
7 days of each visit using INTAKE 24.57 Psychometric 
measures of eating behaviour are assessed at each visit 
using the Three Factor Eating Questionnaire-51,58 the 
Problematic Eating Patterns Scale (unpublished scale), 
Eating in the Absence of Hunger Scale,59 Intuitive Eating 
Scale-260 and the Binge Eating Scale.61
Well-being and quality of life
Quality of life and well-being are assessed using the 5-level 
EQ5D (EQ5D-5L)62 and the Warwick-Edinburgh Well-
Being Scale,63 respectively.
Self-regulation
Self-regulation is measured using the Action Planning 
and Coping Planning Scales64 and Action Control Scale.65
Motivation
Satisfaction of psychological needs are assessed using 
the Basic Psychological Needs and Frustrations Scale.66 
Quality of goal contents is assessed using the Goal Content 
for Weight Loss Maintenance Scale.67 68 Autonomous and 
controlled motivation are assessed using the Behavioural 
Regulation in Exercise Questionnaire (BREQ-3),69 Regu-
lation of Eating Behaviour Scale (REBS)70 and Regula-
tions for Weight Management Scale (adapted from the 
REBS).70
Self-efficacy
Self-efficacy is assessed using the Self-Efficacy for Weight 
Maintenance Scale.71
Emotion regulation and stress management
CB-emotion regulation and stress management constructs 
are measured using the Weight Focused Self-Criticism/
Self-Reassurance Scale,72 Weight Focused External Shame 
Scale,73 74 the Compassion Engagement and Actions 
Scales,75 Body Image Acceptance and Action Question-
naire,76 Engaged Living Scale,77 Mindful Attention Aware-
ness Scale,78 adapted Difficulties in Emotion Regulation 
Scale79 and Experiences Scales (decentering subscale 
only).80 Perceived stress is measured by the Perceived 
Stress Scale.81 Anxiety and depression are measured using 
the Depression & Anxiety Stress Scales.82
Demographics, weight history and participant traits
A profiling questionnaire, adapted from the DiOGenes 
study,83 is administered at baseline only to measure trait-spe-
cific moderators of WLM including the following demo-
graphics: age, gender, country, education, marital status, 
employment and income. Also, smoking and alcohol use 
and number of times giving birth are recorded. Weight 
history includes height, current and highest weight in the 
last 12 months, successful and unsuccessful WL attempts 
and strategies, and psychological impact of living in a 
food abundant environment (the Power of Food Scale).84 
Self-determination traits are assessed using the Index of 
Autonomy Functioning85 and Aspirations Index,86 and 
self-regulation of appetite, hunger and satiety cues by the 
Intuitive Eating Scale-1.87 Relapse prevention capability is 
measured using an adapted Relapse Prevention Scale.88
Process evaluation and user experience
Questionnaires adapted from the Technology Acceptance 
Model for Mobile Services (TAMM)89 are administered 
by email to assess reasons for engagement/dropout and 
user-experience (eg, perceived ease-of-use and adoption, 
perceived value, trust, acceptability and usability). Digital 
literacy is assessed at 1 month using the eHealth Literacy 
Scale (eHEALS).90 Twelve focus groups were conducted 
(four in each country) at 6 months, by independent 
researchers, to thematically explore contextual factors 
(eg, influence of wider social networks), user experience 
and the toolkit use context in the three countries.91 Meta-
data on reach (participant characteristics), dose, fidelity 
and engagement with the toolkit are extracted from log 
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files (online supplementary file 2). Methods and analyses 
will be detailed in separate publications.
data management
A NoHoW data-hub was developed by the James Hutton 
Institute (Edinburgh) and led by GH, which collates, 
monitors and stores anonymised data securely from 
each centre. Data from each centre are entered into 
trial management software (Easy Trial: www. easytrial. 
net). Quality checks are performed by all centres and 
reviewed during weekly trial management meetings. 
Separate publications will detail the technologies to host 
the toolkit, and the ICT architecture linking the toolkit, 
trial administration portal, trial management software 
and NoHoW data-hub.
data analysis
The 2×2 factorial design will be used in a model to investi-
gate links between outcomes, and the extent of mediation 
or moderation by covariates. For continuous outcomes, 
linear regression models will be used. The effects of 
different treatment arms will be presented with 95% CI 
of coefficients and p values. For analyses that do not meet 
model assumptions, outcomes will be transformed prior 
to inferential comparisons. For categorical outcomes, 
logistic regression or categorical response models such as 
ordinal or multinomial regression will be used. Treatment 
effects will be presented as ORs, 95% CIs and p values. 
Missing values will be imputed using multiple imputation 
as part of an intention-to-treat (ITT) analysis.
To determine the mechanisms that underlie interven-
tion efficacy, linear models are used to test whether the 
treatment (independent variable) causes a change in 
the potential mechanisms of change (mediators), which, 
in turn, cause a change in the primary and secondary 
outcomes (dependent variables). Models also investigate 
the effects of covariates that may moderate the effect 
of the interventions. Although a repeated measures/
mixed model might potentially detect treatment effects 
not apparent when 6-month and 12-month outcomes 
are considered separately, our choice was driven by the 
primary role of the 12-month outcome. To be considered 
worthwhile, a WL or maintenance effect of treatment 
must be detectable at 12 months, whatever might happen 
during the time interval between then and baseline. 
Because of this, we chose to define the primary outcome 
and its analysis at 12 months alone.
For the primary outcome of weight, we intend to present 
results from an analysis of completers, of compliant 
participants and of the ITT population. Baseline and last 
observation carried forward are likely to be optimistic 
for dropouts, implying full WLM. So, for these dropouts, 
we will examine analyses which assume regain of all or 
a range of proportions of the weight lost since highest 
weight (in the 12 months before enrolment, for which 
all participants have provided evidence). Again, assuming 
return to baseline may be optimistic, but we do not have 
values at the time of greatest weight. Accordingly, we 
plan multiple imputation based on the imputed weight 
changes described above, using also centre and gender. 
This is not available for other health outcomes, such as 
HbA1c or blood pressure.
Mediation is assessed where change in weight, as repre-
sented by a categorical endpoint (maintenance vs weight 
regain), is the dependent variable, intervention group is 
the predictor variable, and self-regulatory, emotion regu-
latory and other psychosocial variables are mediators. 
Hybrid models, combining latent and observed variables, 
may be specified to ensure sufficient power to conduct 
the analysis and to stay within the limits of sample size 
requirements. Model fit will be assessed using the χ2 
goodness-of-fit test, Bollen’s incremental fit index (0.95) 
and the standardised root mean residual (0.08) values. 
Tests of mediation will be conducted using a resampling 
method. To test the significance of specific indirect 
effects of multiple mediators (total and specific for each 
mediator, using both normal theory and bootstrap proce-
dures), a tool developed by Selig and Preacher92 will be 
used.
subgroup analysis
Interactions between condition factors and baseline 
participant groupings (centre, gender, age, BMI at entry, 
% WL at entry) will be prioritised as a priori subgroup 
analyses in the primary and secondary outcomes. Age, 
BMI and weight will be analysed as categorical variables 
to avoid assumptions of linearity (or the complexity of 
fitting polynomial terms) and for ease of presentation. 
These pre-planned analyses will be conducted by the 
inclusion of appropriate interaction terms in the regres-
sion models. Where interactions are significant, results 
for each subgroup will be reported. This will mitigate 
the problems of multiple testing due to many subgroup 
comparisons. We recognise that statistical power in 
subgroups will vary with sample size and provide a plot 
of detectable effect size versus sample size for reference 
(figure 3).
Cost-effectiveness analyses
Cost-effectiveness analysis will be conducted to model 
costs and intervention effects for a lifetime horizon. An 
existing decision-analytical model will be used to estimate 
BMI category transitions, incidence of secondary diseases 
(eg, type 2 diabetes), quality of life and healthcare costs.93 
Quality-adjusted life-years and costs will allow calculation 
of incremental cost-effectiveness ratios and estimates 
of cost-utility. Extensive sensitivity analyses will test the 
modelling assumptions. Exploration of scenarios relating 
inter alia to the cost and effects (including sustainability) 
of the intervention. Secondary cost-effectiveness analysis 
will explore WLM outcomes (eg, cost per g maintained 
per year). The model will be adapted separately for each 
country.
Power calculations and sample size estimation
Power calculations were based on the primary outcome 
(weight change). To detect a difference between 
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Figure 3 Plot of detectable effect size (Cohen’s d).
treatment arms of >1.5 kg body weight gives a (Cohen's) 
d value of 0.25.22 For 80% power, comparing more than 
two groups requires a sample size of 250 per trial arm. 
To detect an effect size of 0.25 SD units for HbA1c, 245 
participants in each trial arm gives 80% power, at 5% 
significance. Assuming 38% dropout,83 a sample size of 
1600 (533 per centre) is needed to achieve a sample of 
1002 (334 per centre, ~250 per trial arm) participants at 
12 months.
Ethics and dissemination
The trial was registered with the ISRCTN registry 
(ISRCTN88405328). Ethical approval was granted 
by each institutional ethics committee before study 
commencement at each centre. The protocol complies 
with relevant EC legislation, international conventions 
and declarations relating to ethical research practices.94 
Interventions will be discontinued if they are reported 
detrimental. Protocol deviations, violations and serious 
adverse events or adverse events are recorded by trial 
staff and monitored by the principal investigator (RJS) 
and TSC.95 Any protocol amendments that impact the 
study conduct are approved by each institutional ethics 
committee and communicated to participants. Trial 
results will be published in peer-reviewed scientific 
journals. Baseline data will be analysed after the end of 
recruitment (March 2018) and outcome analyses after 
1-year data are collected (March 2019). Authorship will 
be determined by the guidelines set out by the Interna-
tional Committee of Medical Journal Editors.
PotEntIAl outCoMEs And IMPACt
This is the first project to develop and formally eval-
uate (via randomised controlled trial) a new ICT toolkit 
combining continuous tracking of physical activity and 
body weight with theoretically informed, evidence-based 
digital interventions targeting self-regulation and motiva-
tion, and CB-emotion regulation in a 2×2 design, to target 
long-term weight management.
The NoHoW toolkit comprises evidence-based 
behaviour change techniques and CB-emotion regula-
tion strategies, which are hypothesised mechanisms of 
action that may impact EB behaviours and longer term 
weight outcomes. Analyses of primary outcomes will 
enable us to test the hypotheses that self-regulation of 
EB behaviours improves longer term weight outcomes 
and that CB-emotion regulation strategies help prevent 
weight relapse. Secondary outcomes of the trial moder-
ator effects will enable us to determine if different psycho-
logical and behavioural profiles of participants predict 
response to self-regulation or emotion regulation inter-
ventions. Mediation analyses will enable us to determine 
the mechanisms of action by which self-regulation and 
emotion regulation-based behaviour change approaches 
affect EB behaviours and longer term weight and health. 
Secondary analyses will inform more personalised digital 
interventions that better match intervention content 
and delivery to individual user needs, potentially helping 
to improve user engagement, health and well-being of 
participants.
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limitations
Participants are blinded to study allocation, but they can 
access similar interventions from other real-world sources. 
The 2×2 design involved an active control. A 2×2 plus one 
design including a no-intervention control would have 
enabled evaluation of self-tracking using Fitbit devices 
versus no intervention.
The active control arm includes self-monitoring of 
physical activity and weight but the inclusion of the Fitbit 
devices across all arms potentially contaminates or dimin-
ishes the effect of self-regulatory components.
There is a potential conflict inherent in the design of 
trial that seeks to allow a certain degree of personalisation 
of intervention content use and maintain the integrity of 
trial arms. For this reason, the degree of personalisation 
was constrained to choice in the use of available self-reg-
ulatory or contextual emotion regulatory content within 
respective trial arms.
Social support was deliberately not part of this interven-
tion but it is known that the degree of social support can 
be important for weight management.
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